Used in the treatment of non-small cell lung cancer (NSCLC) that is driven by abnormalities in the anaplastic lymphoma kinase (ALK) gene. It is particularly effective against tumors that have developed resistance to other ALK inhibitors. Brigatinib works by blocking the activity of ALK and related proteins, which helps to inhibit the growth and spread of cancer cells. It shows strong activity in both systemic disease and brain metastases, making it valuable for patients with advanced stages of ALK-positive NSCLC. The drug is taken orally and has demonstrated high response rates and prolonged progression-free survival in clinical trials.